A review of design criteria for cancer-targeted, nanoparticle-based MRI contrast agents
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Lanthanide and Transition Metal Complexes · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Applications of nanoparticles in biomedical imaging10.1039/C8NR07769J ↗
2. Engineered gadolinium-based nanomaterials as cancer imaging agents
3. Detection and imaging of gadolinium accumulation in human bone tissue by micro- and submicro-XRF10.1038/s41598-020-63325-9 ↗
4. Stimulus-responsive nanoparticle magnetic resonance imaging contrast agents: design considerations and applications10.1002/adhm.202001091 ↗
5. Metal-based nanoparticle magnetic resonance imaging contrast agents: classifications, issues, and countermeasures toward their clinical translation10.1002/admi.202101710 ↗
6. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites10.1111/jphp.13098 ↗
7. MRI-traceable theranostic nanoparticles for targeted cancer treatment10.7150/thno.48811 ↗
8. MRI, CT, and PETSCAN: engineer's perspective
9. Basics of magnetic resonance imaging and quantitative parameters T1, T2, T2*, T1rho and diffusion-weighted imaging10.1007/s00247-021-05042-7 ↗
10. Neural network in the analysis of the MR signal as an image segmentation tool for the determination of T1 and T2 relaxation times with application to cancer cell culture10.3390/ijms24021554 ↗
11. What are normal relaxation times of tissues at 3 T?10.1016/j.mri.2016.08.021 ↗
12. Magnetic resonance imaging: principles and techniques: lessons for clinicians10.1016/j.jceh.2015.08.001 ↗
13. T1-T2 molecular magnetic resonance imaging of renal carcinoma cells based on nano-contrast agents10.2147/IJN.S168660 ↗
14. Fe3O4/graphene-based nanotheranostics for bimodal magnetic resonance/fluorescence imaging and cancer therapy10.1007/s10904-022-02457-z ↗
15. Structure-relaxivity relationships of magnetic nanoparticles for magnetic resonance imaging
16. Transverse relaxation of solvent protons induced by magnetized spheres: application to ferritin, erythrocytes, and magnetite10.1002/mrm.1910050404 ↗
17. Relaxation processes in a system of two spins10.1103/PhysRev.99.559 ↗
18. Structure-relaxivity relationships of magnetic nanoparticles for magnetic resonance imaging
19. Relaxivity in paramagnetic systems: theory and mechanisms10.1016/j.pnmrs.2006.03.003 ↗
20. Surface impact on nanoparticle-based magnetic resonance imaging contrast agents10.7150/thno.23789 ↗
21. Synthesis and characterization of Gd3+-loaded hyaluronic acid-polydopamine nanoparticles as a dual contrast agent for CT and MRI scans10.1038/s41598-023-31252-0 ↗
22. Ligand design strategies to increase stability of gadolinium-based magnetic resonance imaging contrast agents10.1038/s41467-019-09342-3 ↗
23. Gadolinium-hybridized mesoporous organosilica nanoparticles with high magnetic resonance imaging performance for targeted drug delivery10.1016/j.jcis.2022.11.085 ↗
24. Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration10.1007/s00204-021-03189-8 ↗
25. Gadolinium deposition and nephrogenic systemic fibrosis: a radiologist's primer10.1148/rg.2020190110 ↗
26. Gadolinium-loaded calcium phosphate nanoparticles for magnetic resonance imaging of orthotopic hepatocarcinoma and primary hepatocellular carcinoma10.1039/C9BM01544B ↗
27. Recent advances in development of dendritic polymer-based nanomedicines for cancer diagnosis10.1002/wnan.1670 ↗
28. A nanostrategy for efficient imaging-guided antitumor therapy through a stimuli-responsive branched polymeric prodrug10.1002/advs.201903243 ↗
29. Polymeric dual-modal imaging nanoprobe with two-photon aggregation-induced emission for fluorescence imaging and gadolinium-chelation for magnetic resonance imaging
30. Unimolecular nano-contrast agent with ultrahigh relaxivity and very long retention for magnetic resonance lymphography10.1021/acs.nanolett.2c00796 ↗
31. Comparative study on in vivo behavior of PEGylated gadolinium oxide nanoparticles and Magnevist as MRI contrast agent10.1016/j.nano.2017.12.005 ↗
32. Manganese-based functional nanoplatforms: nanosynthetic construction, physiochemical property, and theranostic applicability10.1002/adfm.201907066 ↗
33. Recent progress on manganese-based nanostructures as responsive MRI contrast agents10.1002/chem.201802851 ↗
34. Carbonized paramagnetic complexes of Mn (II) as contrast agents for precise magnetic resonance imaging of sub-millimeter-sized orthotopic tumors10.1038/s41467-022-29586-w ↗
35. The transition from metal-based to metal-free contrast agents for T 1 magnetic resonance imaging enhancement10.1021/acs.bioconjchem.9b00499 ↗
36. Mn(II) compounds as an alternative to Gd-based MRI probes10.4155/fmc-2018-0608 ↗
37. Manganese in diagnostics: a preformulatory study10.3390/pharmaceutics14010108 ↗
38. A mesoporous polydopamine nanoparticle enables highly efficient manganese encapsulation for enhanced MRI-guided photothermal therapy10.1039/D1NR00957E ↗
39. One-pot preparation of hydrophilic manganese oxide nanoparticles as T1 nano-contrast agent for molecular magnetic resonance imaging of renal carcinoma in vitro and in vivo10.1016/j.bios.2017.10.047 ↗
40. Zwitterionic polydopamine-coated manganese oxide nanoparticles with ultrahigh longitudinal relaxivity for tumor-targeted MR imaging10.1021/acs.langmuir.9b00013 ↗
41. Molecular magnetic resonance imaging using a redox-active iron complex10.1021/jacs.9b00603 ↗
42. Ferritin protein regulates the degradation of iron oxide nanoparticles10.1002/smll.201602030 ↗
43. Low-molecular-weight iron chelates may be an alternative to gadolinium-based contrast agents for T1-weighted contrast-enhanced MR imaging10.1148/radiol.2017170116 ↗
44. Iron(III) chelated paramagnetic polymeric nanoparticle formulation as a next-generation T 1 -weighted MRI contrast agent10.1039/D1RA05544E ↗
45. PCN-Fe(III)-PTX nanoparticles for MRI guided high efficiency chemo-photodynamic therapy in pancreatic cancer through alleviating tumor hypoxia10.1007/s12274-019-2610-6 ↗
46. Ultrasmall superparamagnetic iron oxide nanoparticles: a next generation contrast agent for magnetic resonance imaging10.1002/wnan.1740 ↗
47. Superparamagnetic iron oxide nanoparticles (SPIONs) as therapeutic and diagnostic agents
48. Multifunctional theranostic nanoparticles based on exceedingly small magnetic iron oxide nanoparticles for T 1 -weighted magnetic resonance imaging and chemotherapy10.1021/acsnano.7b04924 ↗
49. Chemistry of MRI contrast agents: current challenges and new frontiers10.1021/acs.chemrev.8b00363 ↗
50. Cu-doped extremely small iron oxide nanoparticles with large longitudinal relaxivity: one-pot synthesis and in vivo targeted molecular imaging10.1021/acsomega.8b03004 ↗
51. Dynamically reversible iron oxide nanoparticle assemblies for targeted amplification of T1-weighted magnetic resonance imaging of tumors10.1021/acs.nanolett.8b04411 ↗
52. Supramolecular and biomacromolecular enhancement of metal-free magnetic resonance imaging contrast agents10.1039/C9SC05510J ↗
53. Self-assembled, biocompatible and biodegradable TEMPO-conjugated nanoparticles enable folate-targeted tumor magnetic resonance imaging
54. Single-layer boron-doped graphene quantum dots for contrast-enhanced in vivo T 1 -weighted MRI10.1039/C9NH00608G ↗
55. Magnetic nanoparticles in nanomedicine: a review of recent advances10.1088/1361-6528/ab4241 ↗
56. Assembly-controlled magnetic nanoparticle clusters as MRI contrast agents10.1021/acsbiomaterials.9b01198 ↗
57. Magnetic nanoparticles in biology and medicine: past, present, and future trends10.3390/pharmaceutics13070943 ↗
58. Nanopharmaceuticals: a focus on their clinical translatability10.1016/j.ijpharm.2020.119098 ↗
59. Iron oxide nanoparticles: diagnostic, therapeutic and theranostic applications10.1016/j.addr.2019.01.005 ↗
60. Advances of functional nanomaterials for magnetic resonance imaging and biomedical engineering applications10.1002/wnan.1800 ↗
61. Nano-confinement-driven enhanced magnetic relaxivity of SPIONs for targeted tumor bioimaging10.1039/C7NR07035G ↗
62. Magneto-Liposomes as MRI contrast agents: a systematic study of different liposomal formulations10.3390/nano10050889 ↗
63. Biomineralization and biotechnological applications of bacterial magnetosomes10.1016/j.colsurfb.2022.112556 ↗
64. Smart bacterial magnetic nanoparticles for tumor-targeting magnetic resonance imaging of HER2-positive breast cancers10.1021/acsami.8b15838 ↗
65. Composition tunable manganese ferrite nanoparticles for optimized T 2 contrast ability10.1021/acs.chemmater.7b00035 ↗
66. Iron carbides: mMagic materials with magnetic and catalytic properties10.1016/j.jmmm.2019.165432 ↗
67. Fe5C2 Nanoparticles with High MRI contrast enhancement for tumor imaging10.1002/smll.201303263 ↗
68. Casein-Coated Fe5C2 nanoparticles with superior r 2 relaxivity for liver-specific magnetic resonance imaging10.7150/thno.12570 ↗
69. Shape-, size- and structure-controlled synthesis and biocompatibility of iron oxide nanoparticles for magnetic theranostics10.7150/thno.25220 ↗
70. Facile synthesis of water-soluble Fe3O4 and Fe3O4@PVA nanoparticles for dual-contrast T1- and T2-weighted magnetic resonance imaging10.1016/j.mri.2022.09.009 ↗
71. T1–T2 dual-modal MRI of brain gliomas using PEGylated Gd-doped iron oxide nanoparticles10.1016/j.jcis.2013.11.020 ↗
72. Albumin-mediated synthesis of fluoroperovskite KMnF3 nanocrystals for T1-T2 dual-modal magnetic resonance imaging of brain gliomas with improved sensitivity10.1016/j.cej.2020.125066 ↗
73. Gd/Y hydroxide nanosheets as highly efficient T1/T2 MRI contrast agents10.3390/nano11010017 ↗
74. Inorganic nanomaterials with rapid clearance for biomedical applications10.1039/D0CS00461H ↗
75. Strategies in the design of nanoparticles for therapeutic applications10.1038/nrd2591 ↗
76. Size, shape, charge and “stealthy” surface: carrier properties affect the drug circulation time in vivo10.1016/j.ajps.2020.07.005 ↗
77. Studying the effect of particle size and coating type on the blood kinetics of superparamagnetic iron oxide nanoparticles10.2147/IJN.S33120 ↗
78. Pharmacokinetics of magnetic iron oxide nanoparticles for medical applications10.1186/s12951-022-01510-w ↗
79. Recent advances in tumor targeting via EPR effect for cancer treatment10.3390/jpm11060571 ↗
80. Engineering tumor-targeting nanoparticles as vehicles for precision nanomedicine
81. Mediating passive tumor accumulation through particle size, tumor type, and location10.1021/acs.nanolett.7b00021 ↗
82. Uptake, distribution, clearance, and toxicity of iron oxide nanoparticles with different sizes and coatings10.1038/s41598-018-19628-z ↗
83. Exerting enhanced permeability and retention effect driven delivery by ultrafine iron oxide nanoparticles with T 1 -T 2 switchable magnetic resonance imaging contrast
84. Effect of micro- and nanoparticle shape on biological processes10.1016/j.jconrel.2021.12.032 ↗
85. Nanotechnology based drug delivery systems: does shape really matter?10.1016/j.ijpharm.2022.122101 ↗
86. Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting10.1002/smll.200801789 ↗
87. The shape effect of magnetic mesoporous silica nanoparticles on endocytosis, biocompatibility and biodistribution10.1016/j.actbio.2016.11.007 ↗
88. Biodistribution and tumors MRI contrast enhancement of magnetic nanocubes, nanoclusters, and nanorods in multiple mice models10.1155/2018/8264208 ↗
89. Charge reversal nano-systems for tumor therapy10.1186/s12951-021-01221-8 ↗
90. Colloidal magnetic resonance contrast agents: effect of particle surface on biodistribution10.1016/0304-8853(93)91115-N ↗
91. The influence of surface charge on the tumor-targeting behavior of Fe 3 O 4 nanoparticles for MRI10.1039/D1TB02349G ↗
92. A new interleukin-13 Amino-coated gadolinium metallofullerene nanoparticle for targeted MRI detection of glioblastoma tumor cells10.1021/jacs.5b03991 ↗
93. A pH-induced charge convertible nanocomposite as novel targeted phototherapy agent and gene carrier10.1016/j.cej.2018.07.145 ↗
94. Stealth coating of nanoparticles in drug-delivery systems10.3390/nano10040787 ↗
95. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery10.1016/j.addr.2015.09.012 ↗
96. Biological effects of formation of protein corona onto nanoparticles10.1016/j.ijbiomac.2021.01.152 ↗
97. Dendrimer-based MRI contrast agents: the effects of PEGylation on relaxivity and pharmacokinetics10.1016/j.nano.2011.03.007 ↗
98. Polyethylene glycol modified, cross-linked starch-coated iron oxide nanoparticles for enhanced magnetic tumor targeting10.1016/j.biomaterials.2010.11.040 ↗
99. Evaluation of PEG-coated iron oxide nanoparticles as blood pool tracers for preclinical magnetic particle imaging10.1039/C6NR08468K ↗
100. Plasma protein adsorption on Fe3O4-PEG nanoparticles activates the complement system and induces an inflammatory response10.2147/IJN.S192214 ↗